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OBJECTIVES This study examined whether long-term therapy with an angiotensin-converting enzyme
(ACE) inhibitor reduces excessive increases in left ventricular (LV) mass as well as volume in
growing children with aortic regurgitation or mitral regurgitation.
BACKGROUND The ACE inhibitor reduces volume overload and LV hypertrophy in adults with aortic or
mitral regurgitation.
METHODS This study included 24 patients whose ages ranged from 0.3 to 16 years at entry to the study.
On echocardiography, we measured LV size, systolic function and mass. After obtaining
baseline data, patients were allocated into two groups. Twelve patients were given an ACE
inhibitor (ACE inhibitor group), and 12 patients were not (control group). Echo parameters
were again assessed after an average 3.4 years of follow-up.
RESULTS Left ventricular parameters at baseline in the two groups were similar. The Z value of LV
end-diastolic dimensions decreased from 10.82 6 0.55 to 10.57 6 0.58 in the ACE
inhibitor group, whereas it increased from 10.73 6 0.85 to 11.14 6 1.04 in the control
group (mean change 20.25 6 0.33 for the ACE inhibitor group vs. 10.42 6 0.48 for the
control group, p 5 0.0007). The mass normalized to growth also reduced from 221 6 93%
to 149 6 44% of normal in the ACE inhibitor group and increased from 167 6 46% to 204 6
59% of normal in the control group (mean change 272 6 89% of normal for the ACE
inhibitor group vs. 137 6 35% of normal for the control group, p 5 0.0007).
CONCLUSIONS Long-term treatment with ACE inhibitors is effective in reducing not only LV volume
overload but also LV hypertrophy in the hearts of growing children with LV volume overload.
(J Am Coll Cardiol 2000;36:270–5) © 2000 by the American College of Cardiology
Chronic volume overload leads to ventricular dilation and
myocardial hypertrophy, which subsequently entails irre-
versible structural and functional damage through a process
known as “cardiomyopathy of overload” (1,2). Therefore, it
should be desirable to prevent development of excessive
cardiac mass. In recent years, several investigators have
reported that prophylactic administration of angiotensin-
converting enzyme (ACE) inhibitor during the stable com-
pensated plateau phase of a chronic volume overload form of
heart disease reduces the extent of ventricular dilation and
excessive mass (3–6) and improves left ventricular (LV)
function (3,5). However, these studies have been limited to
adult patients or older children, and there have been no data
in growing children.
After birth, the heart normally increases in size and mass
with development, and the growth of the ventricle is very
rapid in the neonatal period (7,8) and gradually downregu-
lated with maturation (9,10). Increasing evidence suggests
that locally synthesized angiotensin II is related, at least
partly if not all, to the normal growth of the left ventricle
(7,9–11). Thus, the effects of ACE inhibition could theo-
retically be different in growing children. In the present
study, we tested the hypothesis that long-term therapy with
ACE inhibitor has beneficial effects on the growing left
ventricle of pediatric patients with volume overloaded le-
sions.
METHODS
Study patients. Twenty-four patients with chronic LV
volume load were enrolled in this long-term follow-up
study. The median age of subjects was 3.9 years and ranged
from four months to 16 years at entry to the study. All
patients were asymptomatic but had moderate to severe
cardiomegaly on chest roentogenogram. Sixteen patients
had aortic regurgitation (AR) and eight patients had mitral
regurgitation (MR). Within the AR group, 13 patients had
transposition of the great arteries after the two-staged
arterial switch operation, 2 patients had ventricular septal
defect with right coronary cusp prolapse after intracardiac
repair and 1 had congenital AR. In the MR group, four
patients had atrioventricular canal defect after intracardiac
repair and four patients had ventricular septal defect with
MR after intracardiac repair. None had rheumatic carditis.
Severity of regurgitation was graded by color Doppler flow
mapping using the method described by Omoto et al. (12),
and was severe in 5 patients, moderate in 14 patients and
mild in 5 patients. The follow-up period was from 1.1 to 8.8
years (mean 6 SD 5 3.4 6 2.0 years).
Study protocol. Initial evaluation included a complete
history of symptoms, physical examination, 15-lead electro-
cardiogram, chest roentogenogram and two-dimensional
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echocardiographic study. Thirty-two patients with chronic
LV volume overload initially were enrolled to the study.
After the baseline data were obtained, the 32 patients were
alternately and randomly allocated into two groups. One
group was given an ACE inhibitor (ACE inhibitor group),
and the other group was not (control group). The ACE
inhibitor group initially consisted of 16 patients, including 4
patients who were eventually excluded from analysis because
of paradoxical motion of interventricular septum in 3 and
elevated right ventricular pressure (.40% of systemic pres-
sure) in 1. The control group initially consisted of 16
patients, including 4 patients who were eventually excluded
because of paradoxical motion of interventricular septum.
The characteristics of the 24 patients are listed in Table 1.
Echocardiographic evaluation was repeated at an average of
3.4 years of follow-up after allocation.
Drug administration. Cilazapril was given to nine patients
and enalapril to three patients. Each ACE inhibitor was
started with a low dose, which was increased to the final
dose over 1 to 2 weeks. The final dosage of cilazapril was
0.03 to 0.04 mg/kg/day (maximum dosage 1.0 mg/day) and
the final dose of enalapril was 0.15 to 0.4 mg/kg/day
(maximum dosage 5 mg/day). This final dose was chosen
based on our previous pharmacological study, which dem-
onstrated that it would significantly reduce plasma angio-
tensin II and increase plasma renin activity (unpublished
data).
Other conventional anticongestive drugs being adminis-
tered were digoxin in one patient and diuretics in six
patients in the ACE inhibitor group, and digoxin in one
patient and diuretics in four patients in the control group
(Table 1).
Echocardiographic analysis. Measurements of LV end-
diastolic and end-systolic dimensions and posterior wall
thickness were made from two-dimensionally guided
M-mode recordings. Three to five consecutive cardiac beats
were measured according to the recommendations of the
American Society of Echocardiography (13) and the mean
values were taken. Serial measurements were made by an
observer blinded to patient treatment status. Fractional
shortening and mean velocity of circumferential fiber short-
ening corrected for heart rate were derived from the stan-
dard equations. To adjust for age- and growth-related
changes in echocardiographic variables, LV dimensions and
posterior wall thickness were expressed as a Z-value. The
Z-value was calculated by comparing patient data with our
own normal data from 110 Japanese infants and children.
The formulas for LV dimension and posterior wall thick-
ness were as follows: LV end-diastolic dimension 5 35.1
log BSA 1 40.8 (r 5 0.92, SEE 5 3.2 mm); LV
end-systolic dimension 5 22.0 log BSA 1 26.1 (r 5 0.87,
SEE 5 3.4 mm); posterior wall thickness 5 4.1 log BSA 1
6.1 (r 5 0.85, SEE 5 0.56 mm), where BSA is body surface
area. LV muscle mass was calculated according to the
method of Troy et al. (14) and was expressed as a percentage
of normal.
Interobserver and intraobserver variability. To evaluate
the effect of inter- and intraobserver variability on the
measurements of LV dimensions and posterior wall thick-
ness, 15 randomly selected patients were analyzed at differ-
ent times independently by one researcher (Y.M.) and an
expert technician from our echo laboratory, who had no
knowledge of the patients’ treatment or the results obtained
by the other observer. Measurements were repeated by the
same researcher at least two weeks later to evaluate intraob-
server variability.
Statistical analysis. Values were expressed as mean 6 SD.
Wilcoxon rank sum test and Fisher’s exact test were used for
comparisons of the two groups’ baseline data. The signifi-
cance of treatment effect was determined by comparing the
two groups using two-way repeated-measures analysis of
variance (ANOVA). In addition, a two independent sample
t test was used for comparisons of change from baseline
between the two groups. A p value , 0.05 was considered
statistically significant. Correlation coefficients were used to
compare the two independent observers’ and intraobserver’s
measurements.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
AR 5 aortic regurgitation
LV 5 left ventricular
MR 5 mitral regurgitation








Age (years) 5.0 6 5.2 5.8 6 4.0 0.42
Follow-up period since
diagnosis (years)
3.1 6 1.7 3.7 6 2.2 0.51




Cardiothoracic ratio 0.59 6 0.05 0.58 6 0.05 0.47
Echo Data
LVDd (Z-value) 0.82 6 0.55 0.73 6 0.85 0.53
LVDs (Z-value) 0.90 6 0.54 0.72 6 0.76 0.42
PWT (Z-value) 0.54 6 0.42 0.36 6 0.28 0.25
FS 0.30 6 0.07 0.33 6 0.06 0.51
Rate corrected mVcf 0.94 6 0.21 0.92 6 0.20 0.64
LV mass (% of normal) 221 6 93 167 6 46 0.15
Medications (%)
Digoxin 8 8 0.76
Diuretics 50 33 0.34
Values are mean 6 SD. AR 5 aortic regurgitation; FS 5 fractional shortening;
LVDd 5 left ventricular end-diastolic dimension; LVDs 5 left ventricular end-
systolic dimension; LV mass 5 left ventricular muscle mass; MR 5 mitral regurgi-
tation; mVcf 5 mean velocity of circumferential fiber shortening; PWT 5 posterior
wall thickness.
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RESULTS
Baseline comparisons and follow-up. Clinical character-
istics of the subjects and follow-up period, and measure-
ments of LV dimensions and function at baseline, were
similar between the two groups. While the number of
patients with AR was greater in the control group than in
the ACE group, the difference in incidence was not statis-
tically significant (Table 1). There were no patients who had
side effects or withdrew from the therapy in the ACE
inhibitor group. All study patients were asymptomatic and
none required surgical intervention during the follow-up
period.
Effects of ACE inhibitor on echocardiographic parame-
ters. The results of the two-way repeated-measures
ANOVA for group and time are summarized in Table 2.
The two-way ANOVA showed that there was no overall
significant difference in the mean values of the LV param-
eters between the two groups (p . 0.05 for each LV
parameter) or the two time periods (p . 0.05 for each LV
parameter) (Table 2). However, there was a significant
interaction in the change of all LV parameters but not mean
velocity of circumferential fiber shortening corrected for
heart rate (Table 2). In order to improve the description of
the significant interaction between group and time (for all
outcomes except mean velocity of circumferential fiber
shortening corrected for heart rate), the mean change from
baseline is presented for each group along with the two
independent sample t tests (Table 3). This test is approxi-
mately the same as the test for interaction, as evidenced by
the close correspondence of the t test p values and interac-
tion values from the ANOVA model. This is illustrated in
Figures 1 and 2 by a negative slope for the ACE inhibitor
group and a positive slope for the control group. Thus,
growth-adjusted LV end-diastolic dimensions decreased
from baseline in the ACE inhibitor group over the study
period (Z value 10.82 6 0.55 at baseline vs. 10.57 6 0.58
at follow-up), and they increased from baseline in the
control group (10.73 6 0.85 at baseline vs. 11.14 6 1.04
at follow-up). LV end-systolic dimensions also decreased in
the ACE inhibitor group (Z value 10.90 6 0.54 at baseline
vs. 10.54 6 0.63 at follow-up), whereas they increased in
the control group (10.72 6 0.76 at baseline vs. 11.18 6
0.90 at follow-up) (Fig. 1). There was a significant differ-
ence in the change of LV end-diastolic dimensions and
systolic dimensions from baseline to follow-up between the
two groups (p 5 0.0007 for the LV end-diastolic dimen-
sion, p 5 0.0009 for the LV end-systolic dimension; Table
3).
Fractional shortening increased within the normal range
in the ACE inhibitor group (0.30 6 0.07 at baseline vs.
0.34 6 0.06 at follow-up), and decreased in the control
group (0.33 6 0.06 at baseline vs. 0.31 6 0.05 at follow-
up). There was also a significant difference in the change
from baseline between the two groups (p 5 0.02; Table 3).
However, mean velocity of circumferential fiber shortening
corrected for heart rate stayed within the normal range in
both groups (0.94 6 0.21 at baseline vs. 1.02 6 0.16 at
Figure 1. Changes in left ventricular size. (Top) Left ventricular end-
diastolic dimension (LVDd) decreased in the ACE inhibitor group. In
contrast, it increased in the control group. (Bottom) Left ventricular
end-systolic dimension (LVDs) decreased in the ACE inhibitor group,
whereas it increased in the control group. There was a significant difference
in the change of LVDd and LVDs from baseline to follow-up. Values are
mean 6 SD.








LVDd 0.44 0.33 0.0007
LVDs 0.41 0.62 0.0009
FS 0.96 0.47 0.02
Rate corrected mVcf 0.31 0.5 0.13
PWT 0.32 0.99 ,.0001
LV mass 0.99 0.22 0.0007
ANOVA 5 analysis of variance; LV 5 left ventricular; LVDd 5 left ventricular
end-diastolic dimension; LVDs 5 left ventricular end-systolic dimension; FS 5
fractional shortening; mVcf 5 mean velocity of circumferential fiber shortening;
PWT 5 posterior wall thickness; LV mass 5 left ventricular muscle mass.






LVDd 20.25 6 0.33 10.42 6 0.48 0.0007
LVDs 20.36 6 0.49 10.47 6 0.56 0.0009
FS 10.03 6 0.05 20.02 6 0.05 0.02
Rate corrected mVcf 10.08 6 0.16 20.03 6 0.20 0.13
PWT 20.31 6 0.31 10.47 6 0.56 0.0004
LV mass 272 6 89 137 6 35 0.0007
Values are mean 6 SD. LV 5 left ventricular; LVDd 5 left ventricular end-diastolic
dimension; LVDs 5 left ventricular end-systolic dimension; FS 5 fractional
shortening; mVcf 5 mean velocity of circumferential fiber shortening; PWT 5
posterior wall thickness; LV mass 5 left ventricular muscle mass.
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follow-up in the ACE inhibitor group, 0.92 6 0.20 at
baseline vs. 0.89 6 0.17 at follow-up in the control group),
and there was not a significant difference in the change from
baseline to follow-up between the two groups (p 5 0.13;
Table 3).
Posterior wall thickness adjusted for growth decreased
from 10.54 6 0.42 (Z-value) at baseline to 10.23 6 0.38
at follow-up in the ACE inhibitor group, but it increased
from 10.36 6 0.28 at baseline to 10.67 6 0.26 at
follow-up in the control group (Fig. 2). Left ventricular
muscle mass was 221 6 93% of normal in the ACE
inhibitor group and 167 6 46% of normal in the control
group at baseline. These baseline values were not statistically
different between the two groups (p 5 0.15). The LV
muscle mass decreased from 221 6 93% to 149 6 44% of
normal in the ACE inhibitor group, whereas it increased
from 167 6 46% to 204 6 59% of normal in the control
group (Fig. 2). There was also a significant difference in the
change of posterior wall thickness and mass from baseline
between the two groups (p 5 0.0004 for the posterior wall
thickness, p 5 0.0007 for the LV mass; Table 3).
Interobserver and intraobserver variability. Excellent
correlations were found between the two independent ob-
servers’ measurements of LV dimensions (r 5 0.97, SEE 5
3 mm, p , 0.0001) and posterior wall thickness (r 5 0.94,
SEE 5 0.73 mm, p , 0.0001). The intraobserver variability
was also acceptable for LV dimensions (r 5 0.98, SEE 5
2.3 mm, p , 0.0001) and for posterior wall thickness (r 5
0.96, SEE 5 0.51 mm, p , 0.0001).
DISCUSSION
Treatment with ACE inhibitors acutely reduces regurgitant
volume and improves cardiac performance in AR (15,16)
and MR (17), and chronically decreases LV volume and
hypertrophy in adult patients with AR (3,4) and in dogs
with MR (5). These studies were performed only in adults,
and a recent study of Alehan et al. (6) demonstrated that
one year of captopril therapy significantly reduced LV
volume and mass in children or adolescents with AR, whose
mean age, however, was 14 years. A few studies in pediatric
patients (18,19) have suggested that the benefits of ACE
inhibition in children may be similar to adult patients, but
they did not test its long-term effect. Thus, there has been
virtually no data on long-term efficacy of ACE inhibitors in
growing children.
Our study showed that the volume overload itself in-
creased body size-adjusted LV dimensions and muscle mass
progressively, while children were still growing. These
findings are in striking contrast to the results in adult
patients, which showed that these parameters did not
change during 12 to 24 months in patients with AR without
vasodilator therapy (20,21). Although the follow-up period
between their studies and our study was different, we suspect
that the increase in LV volume and mass in our controls
may be specific for growing children.
It has been demonstrated that a rapid growth of the left
ventricle normally occurs in the neonatal period (7,8) and
the capacity of myocardial remodeling secondary to volume
overload is enhanced during the growth period (22), and
these characteristics are gradually downregulated (9,10,22).
Angiotensin II is one of the important factors for stimula-
tion of normal growth of the heart during childhood as well
as pathological dilatation and hypertrophy (7,9–11,23–27).
In fact, previous studies have shown that ventricular angio-
tensin II mRNA level (10) and density of angiotensin II
receptors (9,10) are significantly higher at the neonatal or
growing period than at the late developmental period, and
they are again downregulated with maturation (10). These
studies indicate that the cardiac renin-angiotensin system
may have played an important role in the significant increase
in LV size and muscle mass observed in our control patients.
The more important finding in our study was that ACE
inhibitor treatment prevented development of excessive LV
muscle mass or even reduced LV muscle mass. ACE
inhibitors are a potent vasodilator and reduce volume load to
the heart, as shown in the previous acute studies (15,16).
This mechanism could be one of the factors related to our
finding. Because we did not compare the effect of ACE
inhibitors with other vasodilators in the present study, we
cannot conclude that only ACE inhibition reduces LV
Figure 2. Changes in posterior wall thickness and left ventricular muscle
mass. (Top) Posterior wall thickness (PWT) decreased in the ACE
inhibitor group, but it increased in the control group. (Bottom) Left
ventricular mass (LV mass) decreased in the ACE inhibitor group, whereas
it increased in the control group. There was a significant difference in the
change of PWT and LV mass from baseline to follow-up. Values are
mean 6 SD.
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muscle mass in growing children with regurgitant lesions.
However, it has been shown in animal studies that ACE
inhibitors can reduce hypertrophy by a process that is
independent of systemic hemodynamics (25,28–31), and
the renin-angiotensin system is known to be highly relevant
in remodeling of the growing heart as described above.
Therefore, the reduction of LV muscle mass would be
largely a result of inhibition of the renin-angiotensin system.
Regardless of precise mechanisms, all of these effects, alone
or in combination with each other, could explain the
prevention of excessive muscle mass development produced
by LV volume overload. Progressive ventricular dilation and
increase in muscle mass are important predictors of the need
for surgical intervention. The results of our study suggest
that ACE inhibitor therapy could delay deleterious struc-
tural changes of the LV myocardium and thus postpone
surgical intervention.
Study limitations. Our study has several limitations that
must be recognized. First, we included patients with both
AR and MR. Also, by the random selection basis of our LV
volume overload patients and the small patient numbers,
AR was more frequent in the control group than in the
ACE inhibitor group. It has been reported that AR may
have a different natural history from MR in adults (32–34).
A cross-over study would be able to overcome this limita-
tion. However, as the study progressed, we found a signif-
icantly better outcome in the ACE inhibitor group, and
therefore we did not feel that it was appropriate or ethical to
perform a cross-over study in the light of our preliminary
data. Second, our follow-up period may not be long enough
to draw a firm conclusion, although three years of follow-up
is comparable with the previous studies of similar design
(3,4,6). Furthermore, it would have been highly desirable to
increase the number of patients in our study, but it was not
practical in one institute because isolated significant aortic
or mitral regurgitation is rather rare in young children.
Multicenter studies will be required to increase the number
of patients for a randomized, double-blinded study.
Conclusions. Our study suggests that long-term treatment
with ACE inhibitor is effective in reducing not only LV
volume but also LV hypertrophy in the volume-overloaded
heart of growing children. Further study is necessary to
demonstrate whether ACE inhibitor treatment specifically
improves the natural history and facilitates delaying heart
surgery in children with aortic or mitral regurgitation.
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